methotrexate oncology
Selected indexed studies
- Methotrexate-induced neurotoxicity in oncology: Current issues for a classic drug. (J Neurol Sci, 2025) [PMID:40328114]
- Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group. (Neuro Oncol, 2025) [PMID:40485042]
- Pharmacokinetic drug-drug interactions with methotrexate in oncology. (Expert Rev Clin Pharmacol, 2011) [PMID:22111860]
_Worker-drafted node — pending editorial review._
Connections
methotrexate oncology is a side effect of
Sources
- Methotrexate-induced neurotoxicity in oncology: Current issues for a classic drug. (2025) pubmed
- Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group. (2025) pubmed
- Pharmacokinetic drug-drug interactions with methotrexate in oncology. (2011) pubmed
- Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. (2022) pubmed
- Methotrexate for gestational choriocarcinoma: a paradigm shift in oncology. (2023) pubmed
- [Methotrexate in gynecologic oncology]. (1996) pubmed
- Methotrexate Scarcity Among Children's Oncology Group Institutions: Results of a Multinational Survey. (2025) pubmed
- Pharmacokinetics and metabolism of methotrexate: an example for the use of clinical pharmacology in pediatric oncology. (1990) pubmed
- Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. (2019) pubmed
- Methotrexate resistance and its regulatory mechanisms in pediatric tumors and beyond. (2025) pubmed